XNCR Stock Analysis: Buy, Sell, or Hold?
XNCR - Xencor, Inc.
$12.36
0.03 (0.24%)
▲
5d:
+8.33%
30d:
+4.04%
90d:
+2.74%
BUY
MODERATE Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When XNCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: XNCR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: XNCR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: XNCR is currently trading at $12.36, which is considered extended relative to its 30-day fair value range of $11.25 to $12.35.
Technical Outlook: Technically, XNCR is in a downtrend. The price is approaching resistance at $12.53. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: XNCR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $28.50 (+131.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XNCR is in a downtrend. The price is approaching resistance at $12.53. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: XNCR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $28.50 (+131.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$11.25 -
$12.35
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 131.1% below Wall St target ($28.50)
Trading Range Analysis
30-Day Trading Range
$11.25 -
$12.35
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$11.08
Resistance Level
$12.53
Current Trend
Downtrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.46
Wall Street Target
$28.50
(+131.1%)
Revenue Growth (YoY)
-86.2%
Profit Margin
-177.1%
Share & Embed Analysis
Last updated: June 15, 2026 10:44 AM ET
Data refreshes hourly during market hours. Next update: 11:44 AM
Data refreshes hourly during market hours. Next update: 11:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XNCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Bassil I Dahiyat
SELL
6606 shares
2026-03-06
Celia Eckert
SELL
1767 shares
2026-03-06
John R Desjarlais
SELL
2502 shares
2026-03-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$102 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 56 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 61 BUY |
